THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Pharma Tech Outlook
Patrick Flanagan, CEOVeristat, a global clinical research organization (CRO) with over 26 years’ experience partnering with start-up to mid-size biotech and pharmaceutical companies, excels in supporting complex trials across a wide range of therapeutic areas. Taking a patient-centric approach, the company is highly innovative and formulates flexible solutions that benefit patients and attracts them to participate in clinical trials. In today’s digital world, patients proactively participate in their health plans and seek information on various diseases and treatments online. Realizing this, Veristat focuses on targeting the potential and intended participants for trials through digital media and online platforms, including patient-centric advertising and branded study websites. Veristat curates highly relevant and appropriate patient populations by leveraging in-house, customized marketing and search engine optimization strategies. These unique to Veristat strategies improve patient recruitment and retention success rates for trials efficiently and cost-effectively.
Study branding tools help build patient catalogs for sites and patients alike. A clear example of this is in placebo studies. Branding became critical for a study Veristat was conducting in moderate to severe COPD patients. The study arms were either active treatment or placebo, leaving patients worried about exacerbation of their indication if they received the placebo and sites uncomfortable with how to address patients’ concerns. “We created a COPD Action Plan, outlining the process by which the site would manage the care of the patient in the event of an exacerbation. Branded materials of the study were presented at the time to consent; overcoming many placebo questions and contributing to an over 200% increase to recruitment in that particular clinical trial,” stated Shaheen Limbada, EVP of Global Operation at Veristat. Additionally, Veristat deployed a digital media strategy coupled with a physician-based call center to raise awareness of clinical trials in nearby areas. Through leveraging their proven site selection strategy, Veristat rapidly started up an additional 35 sites to supplement the overall recruitment approach.
We are continuously working on advancing the trials in a productive and impactful way unique for each clinical setting to ensure we respond to a highly elevated sense of urgency due to the pandemic and evolving client needs
With a robust site selection process, site engagement model, digital media, and a patient-centric approach, patient recruitment increased by 292 percent.
Company
Veristat
Management
Patrick Flanagan, CEO and Shaheen Limbada, Executive Vice President, Global Clinical Operations
Description
Veristat is a scientific minded CRO with a full suite of clinical trial and consultation services. Their agile approach and diverse global team allow them to offer customized solutions from consulting to publishing, regulatory support to data base development and of course First Patient First Visit to Last Patient Last Visit, their expertise is diverse
SOUTHBOROUGH - Veristat, a scientific full-service organization for clinical research and consulting (CRO), has acquired Instat Clinical Research, a CRO specializing in biometrics with a 20-year track record of transforming complex data into precise study results.
This acquisition enhances Veristat's expertise and solutions in the field of biometrics, one of the most impactful activities in clinical research. Instat brings complementary knowledge to Veristat's global data management, biostatistics, and statistical programming teams, with employees in the United States and India. Instat has extensive experience collaborating with clients to optimize the design of clinical studies and the collection, integration, and analysis of data to meet the requirements of global regulatory organizations in the USA, Europe, and Asia. The addition of the location in India complements Veristat's existing office in Taipei, providing customers with access to a 24/7 team to deliver data promptly and shorten drug development cycle times.
"Our customers need to understand the insights gained from their study data during both the design phase and the execution of their study programs and respond quickly," said Patrick Flanagan, Chief Executive Officer of Veristat. "Instat has a proven track record, having supported over 100 sponsor-led clinical studies, authored over 150 statistical analysis plans, and participated in over 30 regulatory submissions. The inclusion of Instat's experienced talent will further strengthen our ability to help customers bring their drugs and biologics to market faster."
Both Veristat and Instat's biometrics teams possess extensive expertise in statistical consulting, clinical data programming, statistical analysis, data management, and project management, supporting the development of complex biological and drug therapies for rare cancers, central nervous system diseases or neurological disorders, endocrine/metabolic disorders, infectious diseases, and various other therapeutic areas.
"With the advancement of biotherapeutics, biometrics, the unique foundation of clinical research, is also evolving," explained Kyle McBride, CEO and co-founder of Instat. "Instat possesses the ideal blend of talent, technical acumen, and technological solutions to keep pace with this transformation and impart statistical understanding for the entire lifecycle of clinical development. On behalf of the entire Instat team, we look forward to collaborating with Veristat with confidence and are excited to embark on our next chapter together. Our joining enables us to offer our customers world-class end-to-end services while operating at the speed and effectiveness our customers expect from us."